# Vericel awarded up to $197 million BARDA contract for NexoBrid procurement and development

Vericel Corporation was awarded a ten-year contract valued at up to $197 million by BARDA for procurement of NexoBrid, establishment of a Vendor Managed Inventory system, design of a U.S.-based manufacturing facility, and development of a next-generation formulation and blast trauma indication.

- Type: Contract
- Announced: 2026-04-01
- Where: United States
- Value: $197.0M
- Status: completed
- Products: NexoBrid (enzymatic debridement agent for severe burns)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Vericel Corporation](https://endata.com/companies/91186.md)
- [Biomedical Advanced Research and Development Authority](https://endata.com/companies/8807.md) (customer)

## Sources

- [barchart.com](https://www.barchart.com/press-releases/1121916/vericel-announces-barda-award-valued-at-up-to-197-million-for-procurement-and-advanced-development-of-nexobrid), 2026-04-02: "Vericel Corporation has been awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA) for the procurement of NexoBrid."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.